Medical/Pharmaceuticals
DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQure™)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- DeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), today announced initiation of its Early Feasibility Study (EFS) for the HyperQure™ system following FDA IDE ap...
2024-06-10 13:14
2267
United Imaging Prepares to Ship its 30,000th Unit Globally, a uMI Panorama GS, from Houston for U.S. Installation
The uMI Panorama GS is among the all-digital Molecular Imaging systems United Imaging is featuring at SNMMI in Toronto SHANGHAI, June 8, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is on the brink of a significant milestone as it a...
2024-06-08 21:00
4824
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened fromMay 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessio...
2024-06-07 14:51
2282
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
* According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. * MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activit...
2024-06-06 19:52
2458
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of...
2024-06-06 19:00
2251
ECHO IQ TECHNOLOGY CHAMPIONED IN INDEPENDENT SCIENTIFIC REVIEW
Echo IQ's EchoSolv-AS decision-support software for cardiology delivers significant potential benefits to hospital networks according to independent scientific presentation at prestigious New York Valves scientific conference. NEW YORK, June 6, 2024 /PRNewswire/ -- At the Structural Heart Summit ...
2024-06-06 13:14
2479
STRENGTHENING PATIENT CARE AND SAFETY IN COMPLEX, HIGH-RISK PAEDIATRIC LIVER TRANSPLANT SURGERY
Innovative mixed reality technology enhances pre-surgical planning at NUH's specialised paediatric organ transplant centre inSingapore SINGAPORE, June 5, 2024 /PRNewswire/ -- For the last three decades, the transplant team at theNational University Hospital (NUH)'s Department of Paediatric Surg...
2024-06-05 22:00
2874
Pricing plan from Done aims to make diagnosis and treatment of ADHD more accessible and affordable
SAN FRANCISCO, June 5, 2024 /PRNewswire/ -- Healthcare can be a significant financial burden on many individuals and families, even with insurance. The costs associated with one of the more common health issues in the US, the diagnosis and treatment of adult ADHD, can spill over into many aspects...
2024-06-05 22:00
2716
Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy
SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relaps...
2024-06-05 19:59
2687
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prost...
2024-06-05 19:00
2554
GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024
YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Conducted...
2024-06-05 14:00
2554
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical data of olvere...
2024-06-05 11:46
2290
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a global,...
2024-06-05 11:31
2044
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial C...
2024-06-04 20:50
2283
FDA Clearance For Gastrointestinal Parasite Detection Kit
MELBOURNE, Australia, June 4, 2024 /PRNewswire/ -- Genetic Signatures Limited [ASX:GSS]("GSS" or the "Company"), a global molecular diagnostics company announces that the US Food & Drug Administration ("FDA") has cleared the Company'sEasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 aut...
2024-06-04 19:00
2005
Qingsong Health Corporation Elevates Healthcare and Inclusive Development with AI Advancements at WSIS+20 Forum
BEIJING, June 4, 2024 /PRNewswire/ -- At The World Summit on the Information Society (WSIS) Forum inGeneva, the Qingsong Health Corporation from China, known for its technology-driven healthcare solutions, showcased the latest AI advancements for improved and inclusive healthcare. The WSIS+20 For...
2024-06-04 16:04
1812
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings
YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...
2024-06-04 13:00
2191
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase...
2024-06-04 12:51
2184
Fapon Biopharma Announces a Safer Immunotherapy for Cancers
SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...
2024-06-04 09:42
1496
Datasea Agreement already provided $2.8 million Information Service for its Highly Specialized 5G-AI Communications Platform
Agreement to Have Powerful Revenue Impact and is Expected to Lead to More Lucrative Contracts BEIJING, June 3, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada company engaged in innovative business segments in high-tech intelligent acoustics and 5G-Artifici...
2024-06-03 22:00
3779
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 290 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09